NASDAQ: SPRBSpruce Biosciences Inc Stock
$2.34+0.00 (+0%)
Updated Jun 5, 2023
SPRB Price
$2.34
Fair Value Price
$3.38
Market Cap
$93.01M
52 Week Low
$0.96
52 Week High
$3.57
P/E
-1.26x
P/B
0.86x
P/S
35.9x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.96M
Earnings
-$47.21M
Gross Margin
100%
Operating Margin
-2,380.04%
Profit Margin
-2,403.7%
Debt to Equity
0.29
Operating Cash Flow
-$42M
Beta
1.26
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SPRB Overview
Spruce Biosciences Incorporated develops and commercializes novel therapies for rare endocrine disorders. It is developing Tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from Congenital Adrenal Hyperplasia (CAH), which is in a Phase 2b clinical trial. Spruce Biosciences was incorporated in 2014 and is headquartered in Daly City, CA.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SPRB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SPRB ($2.34) is undervalued by 30.68% relative to our estimate of its Fair Value price of $3.38 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
SPRB ($2.34) is significantly undervalued by 30.68% relative to our estimate of its Fair Value price of $3.38 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
SPRB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SPRB due diligence checks available for Premium users.
Be the first to know about important SPRB news, forecast changes, insider trades & much more!
SPRB News
Valuation
SPRB fair value
Fair Value of SPRB stock based on Discounted Cash Flow (DCF)
Price
$2.34
Fair Value
$3.38
Undervalued by
30.68%
SPRB ($2.34) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SPRB ($2.34) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SPRB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SPRB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.26x
Industry
11.59x
Market
53.21x
SPRB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.86x
Industry
5.21x
SPRB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SPRB's financial health
Profit margin
Revenue
$2.0M
Net Income
-$12.8M
Profit Margin
-651.3%
SPRB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SPRB's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$139.1M
Liabilities
$31.1M
Debt to equity
0.29
SPRB's short-term assets ($137.24M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SPRB's short-term assets ($137.24M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SPRB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.8M
Investing
$10.5M
Financing
$50.5M
SPRB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SPRB vs Biotech Stocks
Spruce Biosciences Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.